Log In
BCIQ
Print this Print this
 

Posiphen

  Manage Alerts
Collapse Summary General Information
Company Horizon Pharma plc
DescriptionAmyloid precursor protein (APP), alpha synuclein (SNCA), and microtubule-associated protein tau (tau; MAPT; FTDP-17) inhibitor
Molecular Target Amyloid precursor protein (APP) ; Alpha synuclein (SNCA)
Mechanism of ActionAmyloid precursor protein (APP) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$800.0M

$800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/25/2016

$800.0M

$800.0M

0

02/04/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today